title: Vemurafenib-induced hyperkeratosis of the areola treated with topical adapelene.
abstract: We present a rare condition, hyperkeratosis of the areola, induced by vemurafenib. Only a few papers have described an association of BRAF inhibitors with hyperkeratosis of the areola and/or nipple. Vemurafenib is a selective BRAF inhibitor used in patients with unresectable or metastatic melanoma who are positive for the V600 mutation. This drug has been associated with numerous cutaneous side effects, both benign and malignant. We report a male patient with vemurafenib-induced hyperkeratosis of the areola managed successfully with a topical retinoid, and describe for the first time a treatment for this side effect.
authors.affiliation: Dorset County Hospital, Dorchester, UK.
authors.forename: E
authors.initials: E
authors.lastname: Martinez-Garcia
authors.affiliation: Dorset County Hospital, Dorchester, UK.
authors.forename: S
authors.initials: S
authors.lastname: Taibjee
authors.affiliation: Dorset County Hospital, Dorchester, UK.
authors.forename: D
authors.initials: D
authors.lastname: Koch
authors.affiliation: Dorset County Hospital, Dorchester, UK.
authors.forename: R
authors.initials: R
authors.lastname: Osborne
mesh_terms: D000068816:Adapalene / Q000008:administration & dosage*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007642:Keratosis / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009558:Nipples; D013449:Sulfonamides / Q000009:adverse effects*; D016896:Treatment Outcome; D000077484:Vemurafenib
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D007211:Indoles; D013449:Sulfonamides; D000068816:Adapalene; D000077484:Vemurafenib